[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guangzhou University of Traditional Chinese Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":407},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,42,65,95,124,150,178,197,223,247,273,300,322,351,384],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100618859","electro-acupuncture-in-lung-cancer--ealer-study-100618859",false,"NCT07337096","Electro-Acupuncture in Lung cancER : EALER Study","Electro-acupuncture Plus PD-1 Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer: A Randomized Trial","Inclusion Criteria:\n\n1. Pathologically confirmed NSCLC, with AJCC lung cancer TNM stage IV.\n2. Tumor proportion score for PD-L1 \\\u003C 50%.\n3. Lacks targetable gene mutations (including but not limited to EGFR mutations or ALK fusions).\n4. No prior systemic therapy for advanced NSCLC (including chemotherapy, targeted therapy, or immunotherapy). Patients planned to receive first-line (induction) treatment with ICIs plus chemotherapy are eligible. Patients who have received prior neoadjuvant or adjuvant therapy, or definitive chemoradiotherapy, may be enrolled if provided that disease progression occurred more than 6 months after the completion of the last treatment.\n5. ECOG performance status score of 0-2.\n6. Age ≥ 18 years.\n7. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n8. Adequate organ function (hematology: ANC ≥ 1500\u002FmcL, PLT ≥ 100,000\u002FmcL, Hb ≥ 9.0 g\u002FdL or ≥ 5.6 mmol\u002FL; renal function: estimated creatinine clearance ≥ 50 mL\u002Fmin; hepatic function: serum total bilirubin ≤ 1.5 × ULN or total bilirubin \\> 1.5 × ULN with direct bilirubin ≤ ULN, AST and ALT ≤ 2.5 × ULN ≤ 5 × ULN for patients with liver metastases).\n9. Voluntary participation in the study, signed informed consent form, good compliance, and cooperation with follow-up.\n\nExclusion Criteria:\n\n1. Inability to complete baseline assessments.\n2. Pregnant or lactating women, and those with psychiatric, intellectual, or language disorders.\n3. Patients with autoimmune diseases or hematologic disorders requiring long-term use of hormones or immunosuppressants.\n4. Presence of concurrent primary malignant tumors at other sites.\n5. Participation in another investigational drug or device clinical trial within 30 days prior to the planned initiation of study treatment.\n6. Known seropositivity for human immunodeficiency virus (HIV), other congenital or acquired immunodeficiencies, or history of organ or stem cell transplantation (including autologous bone marrow or peripheral blood stem cell transplantation).\n7. Loss of self-care capacity, or any medical, psychological, or ethical condition that, in the investigator's judgment, could interfere with the patient's ability to complete the study.\n8. Active skin infection, ulceration, or lesion at acupuncture point sites that would preclude safe administration of treatment.\n9. Implanted cardiac pacemaker or other active implantable electronic medical device.\n10. Severe needle phobia that would prevent acceptance of needling procedures required by the study protocol.\n11. Receipt of any acupuncture or related needle-based therapy within 6 weeks prior to enrollment.\n12. Active pneumonitis, or radiation pneumonitis requiring treatment with systemic corticosteroids.\n13. Active infection requiring antimicrobial therapy (antibacterial, antifungal, or antiviral agents) according to clinical guidelines at the time of screening. Enrollment may be reconsidered after the infection has been adequately controlled.\n14. Active tuberculosis infection, or any severe or uncontrolled systemic illness, including but not limited to clinically significant neurological conditions (e.g., uncontrolled seizures, dementia), unstable or decompensated respiratory, cardiac, hepatic, or renal disease.","ALL","18 Years",{"count":19,"type":20},424,"ESTIMATED","INTERVENTIONAL",[23],"NA","This multicentre, randomized controlled trial evaluates the effect and safety of acupuncture combing with PD-1 inhibitors plus chemotherapy in NSCLC. Participants will be randomly assigned to undergo either acupuncture or sham acupuncture concurrent with the initial four-six cycles of chemotherapy combined with PD-1 inhibitors.",[26,27,28],"Non Small Cell Lung Cancer","Accupuncture","PD-1 Inhibitors","RECRUITING","2026-06-22",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":33},"2026-01-15",{"date":37,"type":20},"2028-12",{"name":39,"class":40},"Guangzhou University of Traditional Chinese Medicine","OTHER",3,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100638433","yiqi-huayu-jiedu-therapy-for-non-surgical-supratentorial-hypertensive-intracerebral-hemorrhage-100638433","NCT07580235","Yiqi Huayu Jiedu Therapy for Non-Surgical Supratentorial Hypertensive Intracerebral Hemorrhage","Clinical Study of Yiqi Huayu Jiedu Therapy in Non-Surgical Patients With Supratentorial Hypertensive Intracerebral Hemorrhage","CHAIN2","Inclusion Criteria:\n\n1.Adults aged 18 years or older, with no restriction on sex. 2.6 to 48 hours after symptom onset; if the exact onset time cannot be determined, the time shall be calculated from the last known well.\n\n3.Patients meeting the traditional Chinese medicine syndrome criteria of \"Qi deficiency, blood stasis, and toxin-induced injury to the brain collaterals.\" Diagnosis shall be based on the Expert Consensus on Integrated Traditional Chinese and Western Medicine for Cerebral Hemorrhage (T\u002FCAIM 023-2021) issued by the Chinese Association of Integrative Medicine.\n\n4.Imaging-confirmed supratentorial hypertensive intracerebral hemorrhage (HICH) located in the basal ganglia, thalamus, lobar region, or subcortical white matter, with a hematoma volume of 15-60 mL.\n\n5.NIHSS score ≥ 8 and GCS score \\> 7. 6.The patient or the patient's legally authorized representative has provided written informed consent\n\nExclusion Criteria:\n\nPatients meeting \\*\\*one or more\\*\\* of the following criteria will be excluded:\n\n1. Intracerebral hemorrhage secondary to structural brain abnormalities, including but not limited to cerebral vascular malformation, intracranial aneurysm, malignant tumor, moyamoya disease, trauma, previous ischemic stroke, cerebral amyloid angiopathy, thrombolysis or thrombectomy, anticoagulant therapy, or other causes of secondary intracerebral hemorrhage.\n2. Patients who, in the judgment of the treating physician, are unlikely to benefit from the trial, have an extremely high risk of early death, or are considered unsuitable for participation by the investigator, such as patients with advanced dementia.\n3. Conditions that may interfere with follow-up or outcome assessment, such as known significant pre-stroke disability, modified Rankin Scale score of 3-5, end-stage malignancy, or renal failure.\n4. Indications for decompressive craniectomy, including but not limited to coma or progressive deterioration of consciousness, large hematoma with significant midline shift, intracranial hypertension difficult to control with medical treatment, cerebral herniation or impending herniation, or marked mass effect on imaging, such as midline shift \\>10 mm or compression\u002Fdisappearance of cisterns or sulci.\n5. Known allergy to any traditional Chinese medicine component of the mixture.\n6. Pregnant or lactating women.\n7. Participation in another clinical trial that may interfere with the evaluation of this study.",{"count":51,"type":20},902,[23],"This multicenter, prospective, double-blind, randomized controlled trial will enroll 902 non-surgical patients with supratentorial hypertensive intracerebral hemorrhage who meet the traditional Chinese medicine syndrome criteria of Qi deficiency with blood stasis and toxin-induced injury to the brain collaterals.\n\nThe primary efficacy endpoint is the proportion of patients achieving a favorable outcome, defined as a modified Rankin Scale score of 0-2 at 180 days after treatment. Participants will be allocated across three trial regions: South China, Northeast China, and East China, with target enrollments of 400, 300, and 202 patients, respectively. Using a central randomization system, patients will be stratified by study center, hematoma volume, and severity of neurological deficit, and randomized 1:1 to the experimental group or control group.\n\nThe experimental group will receive Yiqi Huayu Jiedu Mixture, composed of red ginseng, Panax notoginseng, and raw rhubarb, while the control group will receive a matching placebo. Both interventions will be administered for 28 days, in addition to standardized conventional Western medical treatment.\n\nClinical and imaging data will be collected at multiple time points throughout the study. The primary outcome is the favorable prognosis rate at 180 days. Secondary outcomes include neurological function, quality of life, hematoma and perihematomal edema volume, and other relevant indicators. Adverse events will be monitored to evaluate the safety and efficacy of the mixture in reducing mortality and disability among patients with hypertensive intracerebral hemorrhage.",[55],"Intracranial Hemorrhage, Hypertensive","NOT_YET_RECRUITING","2026-05-11",{"date":59,"type":33},"2026-05-12",{"date":61,"type":20},"2026-08-01",{"date":63,"type":20},"2030-02-01",{"name":39,"class":40},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":75,"conditions":76,"keywords":81,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100619772","pulsatile-high-dose-furmonertinib-in-egfr-mutant-nsclc-with-leptomeningeal-metastasis-100619772","NCT07348965","Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis","Inclusion Criteria:\n\n1. Patients with non-small cell lung cancer (NSCLC) confirmed by histopathological or cytopathological examination\n2. Patients with EGFR exon 19 deletion or exon 21 L858R mutation\n3. Patients with leptomeningeal metastasis (LMD) confirmed by positive cerebrospinal fluid (CSF) cytology (within 28 days prior to the first dose administration) and with at least 1 LMD lesion that can be repeatedly evaluated by magnetic resonance imaging (MRI)\n4. Patients with disease progression after first-line tyrosine kinase inhibitor (TKI) treatment\n5. Aged ≥18 years and ≤85 years, with no gender restrictions.\n6. Sufficient organ function, defined as: absolute neutrophil count ≥ 1.5×10⁹\u002FL, platelet count ≥ 75×10⁹\u002FL, hemoglobin ≥ 90g\u002FL total bilirubin ≤ 1.5×upper limit of normal (ULN) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN (for patients with liver metastasis, total bilirubin can be relaxed to ≤ 3×ULN, and ALT\u002FAST can be relaxed to ≤ 5×ULN) serum creatinine ≤ 1.5×ULN or creatinine clearance ≥ 50 mL\u002Fmin (calculated by the Cockcroft-Gault formula)\n7. For patients enrolled in the pharmacokinetic study: no prior treatment with furmonertinib (either in combination or as monotherapy)\n8. Patients who have signed the informed consent form, are willing to receive treatment under this protocol, can adhere to medication administration, and have good compliance.\n\nExclusion Criteria:\n\n1. Unable to complete the baseline assessment form\n2. Complicated with severe or uncontrolled systemic diseases, including active infection, electrolyte disturbance, bleeding tendency, etc.\n3. Pregnant or lactating women, or those with planned pregnancy during the study or within 6 months after the study ends\n4. Presence of central nervous system complications requiring emergency neurosurgical intervention\n5. Suffering from other malignant tumors or having a history of other malignant tumors\n6. Complicated with severe brain diseases or mental illnesses that affect the patient's ability to report symptoms by themselves\n7. Individuals without legal capacity, or those for whom medical or ethical reasons affect the continuation of the study\n8. Other circumstances deemed unsuitable for participation in this study by the researcher.\n9. Patients with a severe allergic diathesis, especially those who have experienced severe drug allergies or other serious adverse reactions during previous treatment with tyrosine kinase inhibitors (TKIs).","75 Years",{"count":73,"type":20},42,[23],"The goal of this clinical trial is to clarify the efficacy and safety of the high-dose alternate-day furmonertinib in NSCLC with leptomeningeal metastasis. It will also explore the mechanism by which the high-dose alternate-day administration regimen enhances efficacy from a pharmacokinetic perspective, and investigate the impact of co-occurring mutations on the efficacy and prognosis of furmonertinib in the treatment of EGFR-mutant NSCLC with leptomeningeal metastasis. The main questions it aims to answer are:\n\nDoes the high-dose alternate-day administration regimen have definite efficacy? Does the high-dose alternate-day administration regimen have favorable safety? Does the high-dose alternate-day administration regimen improve efficacy by increasing the cerebrospinal fluid (CSF) concentration and CSF penetration rate of the drug? Which co-occurring mutations may affect the efficacy and prognosis of patients with EGFR-mutant NSCLC and leptomeningeal metastasis? Participants will enter Cohort A (320mg qod po) or Cohort B (160mg qd po) to receive furmonertinib based on their own willingness and the clinician's decision, until disease, progression or uncontrollable adverse reactions occur. All patients in Cohort A will undergo efficacy and safety evaluation, with some also participating in pharmacokinetic study; patients in Cohort B will only undergo pharmacokinetic study.\n\nEfficacy and safety evaluation will be conducted through imaging examinations, neurological function assessment scales, quality of life self-assessment scales, and adverse event records. Pharmacokinetic study will be carried out by detecting the plasma concentrations and CSF concentrations of furmonertinib and its active metabolites, and calculating the CSF penetration rate for evaluation.",[77,78,79,80],"NSCLC (Advanced Non-small Cell Lung Cancer)","Leptomeningeal Metastasis","Furmonertinib","EGFR Activating Mutation",[82,83,84,85],"NSCLC","furmonertinib","leptomeningeal metastasis","cerebrospinal fluid","2026-03-31",{"date":88,"type":33},"2026-04-02",{"date":90,"type":33},"2026-03-01",{"date":92,"type":20},"2028-12-31",{"name":39,"class":40},1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":16,"minAge":17,"maxAge":71,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":94},"100468327","efficacy-and-safety-of-hgxjt-in-bone-metastatic-nsclc-patients-100468327","NCT05378334","Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients","Efficacy and Safety of Bone-protecting and Mass-dispersesing Decoction (HuGuXiaoJiTang, HGXJT) Combining With ICIs in Bone Metastatic NSCLC Patients","Inclusion Criteria:\n\n1. Patients with non-small cell lung cancer diagnosed by histopathology or cytopathology.\n2. Presence of bone metastases.\n3. EGFR\u002FALK gene wild type.\n4. No prior treatment with PD-1 inhibitors (combination or monotherapy)\n5. Those who have not received prior antitumor therapy or have not received further antitumor therapy after failure of first-line antitumor therapy.\n6. PS score (ECOG) ≤ 2 points\n7. Normal hepatic and renal function.\n\n   Normal hepatic function: total serum bilirubin level ≤ 1.5 times of the upper limit of normal value(ULN), serum serum aspartate aminotransferase(AST) \\& alanine aminotransferase(ALT) ≤ 2.5 times ULN\n\n   Normal renal function: serum creatinine ≤ 1.5 mg\u002Fdl (133 μmol\u002FL) and\u002For creatinine clearance ≥ 60 ml\u002Fmin.\n8. Presence of at least one assessable lesion.\n9. Signed informed consent, patient willing to accept this regimen, able to adhere to the medication, and good compliance.\n\nExclusion Criteria:\n\n1. Unable to complete the baseline assessment form\n2. Combination of other serious illnesses, including uncontrolled active infection, severe electrolyte disturbances, and significant bleeding tendencies.\n3. Pregnant or lactating women.\n4. Combined autoimmune diseases, hematologic disorders, or long-term use of hormones or immunosuppressive drugs.\n5. Combination of other uncontrolled tumors.\n6. Combination of severe brain or mental illness that affects the patient's ability to self-report.\n7. Combined organ transplant history (including bone marrow autotransplantation and peripheral stem cell transplantation).\n8. Those who are legally incompetent and whose medical or ethical reasons affect the continuation of the research.",true,{"count":104,"type":20},82,[23],"This is a double-blind, randomized controlled study evaluating the efficacy and safety of HGXJT in combination with ICI-based standard treatment in lung cancer patients with bone metastases. Enrolled participates will randomly receive HGXJT or placebo during the first 4-6 cycles of ICI-based standard treatment.",[108],"Non-small Cell Lung Cancer",[110,111,112,113,114,115],"Non-Small Cell Lung Cancer","Bone Metastatic","Immune Checkpoint Inhibitors","Chinese Formula","Efficacy","Safety","2026-03-07",{"date":118,"type":33},"2026-03-10",{"date":120,"type":33},"2022-06-15",{"date":122,"type":20},"2028-01-01",{"name":39,"class":40},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":133,"studyType":134,"phases":4,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},"100618959","a-prospective-multicenter-study-of-the-association-between-tcm-syndromes-and-egfr-tki-efficacy-in-lung-cancer-patients-100618959","NCT07338396","A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients","A Clinical Study on the Patterns of Traditional Chinese Medicine Syndromes and Efficacy Differences in Lung Cancer Patients Treated With EGFR-TKI","Inclusion Criteria:\n\n* Pathologically or histologically confirmed non-small cell lung cancer (NSCLC)\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Presence of epidermal growth factor receptor (EGFR) mutation confirmed by genetic testing\n\nPostoperative Cohort (must meet all of the above and the following):\n\n* Have undergone curative surgery for lung cancer with R0 resection\n* Are planned to receive or are currently receiving postoperative EGFR-TKI adjuvant therapy within 2 weeks\n\nAdvanced Cohort (must meet all of the above and the following):\n\n* Meet stage IIIB-IV criteria according to the 9th edition of the American Joint Committee on Cancer (AJCC), or have stage IIIB or below disease but have refused or are unable to tolerate surgical treatment\n* Have at least one measurable lesion\n* Are planned to receive or are currently receiving first-line EGFR-TKI therapy within 2 weeks\n\nExclusion Criteria:\n\n* Unable to comply with baseline assessments\n* Pregnant or breastfeeding women\n* Presence of other uncontrolled malignancies\n* Presence of severe brain diseases or psychiatric disorders that affect the patient's ability to communicate or provide informed consent\n* Individuals without legal capacity, or those with medical or ethical reasons preventing continued participation in the study\n* Refusal to sign the informed consent form",{"count":132,"type":20},3000,"3 Years","OBSERVATIONAL","The goal of this observational study is to learn about the relationship between TCM body constitution patterns (called \"syndromes\") and the effectiveness of EGFR-TKI targeted drugs in patients with lung cancer. Approximately 3000 patients with EGFR-mutant non-small cell lung cancer who are about to start or are already taking EGFR-TKI drugs as part of their regular medical care will be invited to join. Participants will be followed for up to 5 years. During routine clinic visits, researchers will collect their TCM information (such as tongue images and pulse readings) and store small samples of their blood, stool, and tongue coating for future research.",[137],"Non Small Cell Lung Cancer NSCLC",[137,139,114,140],"Traditional Chinese Medicine Syndromes","EGFR-TKI","2026-01-05",{"date":143,"type":33},"2026-01-13",{"date":145,"type":20},"2026-01",{"date":147,"type":20},"2031-07",{"name":39,"class":40},6,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":4},"100602252","phase-4-traditional-chinese-medicine-intervention-for-ischemic-cerebrovascular-disease-and-diabetes-mellitus-an-efficacy-comparative-study-100602252","NCT07121088","Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Comparative Study","Comparative Effectiveness Study of Traditional Chinese Medicine Intervention in Ischemic Cerebrovascular Disease Comorbid With Diabetes Mellitus","TIDES","Inclusion Criteria:\n\n1. Age ≥ 18 years old, regardless of gender.\n2. Previously diagnosed with diabetes, or with an unknown medical history, meeting the WHO 2023 diagnostic criteria for type 2 diabetes, including any of the following:\n\n   * Fasting blood glucose ≥ 7.0 mmol\u002FL.\n   * 2-hour postprandial blood glucose ≥ 11.1 mmol\u002FL.\n   * Glycated hemoglobin ≥ 6.5%.\n3. Acute cerebral infarction meets the diagnostic criteria of \\*Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023\\*:\n\n   * Acute onset.\n   * Focal neurological deficits, with a few cases showing global neurological deficits.\n   * The presence of a responsible lesion on imaging or symptoms\u002Fsigns persisting for more than 24 hours.\n   * Exclusion of non-vascular etiologies.\n   * Exclusion of intracerebral hemorrhage by brain CT\u002FMRI.\n4. Onset of cerebral infarction \\\u003C 48 hours.\n5. TCM syndrome conforms to the \"toxin damaging brain collaterals\" syndrome (referring to the diagnostic criteria (draft) of \\*Research on the Diagnostic Criteria for the Syndrome of Mutual Binding of Stasis and Toxin in Ischemic Cardiovascular and Cerebrovascular Diseases\\* (Ju Jianqing et al., 2023)).\n6. Modified Rankin Scale (mRS) before onset: 0 - 1 point.\n7. National Institutes of Health Stroke Scale (NIHSS) at admission: 4 - 24 points.\n8. Signed informed consent form.",{"count":159,"type":20},3666,[161],"PHASE4","The objective of this observational study is to understand the long-term effects of traditional Chinese medicine (TCM) intervention on patients with cerebral infarction onset within \\\u003C48 hours and comorbid diabetes. The primary question it aims to address is:\n\nCan long-term TCM intervention for the treatment of ischemic cerebrovascular disease comorbid with diabetes improve patients' neurological deficits and self-care ability? Participants receiving TCM intervention (universal treatment combined with syndrome-specific treatment) as part of routine cerebrovascular disease management will undergo follow-up assessments at 30 days, 90 days, 6 months, and 12 months within 1 year to evaluate neurological status (e.g., mRS score, NIHSS score) and quality of life indicators.",[164,165],"Ischemic Cerebral Infarction","Diabetes Mellitus",[167,168,169],"diabetes mellitus","ischemic cerebral infarction","Chuanzhitongluo capsule","2025-08-12",{"date":172,"type":33},"2025-08-13",{"date":174,"type":20},"2025-08-31",{"date":176,"type":20},"2027-12-31",{"name":39,"class":40},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":94},"100602224","real-world-study-on-chinese-medicine-for-treating-chikungunya-fever-100602224","NCT07120724","Real-World Study on Chinese Medicine for Treating Chikungunya Fever","Efficacy and Safety of Chinese Medicine in the Treatment of Chikungunya Fever: A Real-World Observational Study","Inclusion Criteria:\n\n1. Meets the suspected or confirmed diagnostic criteria for chikungunya fever;\n2. Symptom onset ≤3 days before enrollment;\n3. Actual prescribed treatment aligns with the study's group assignment (TCM, Western medicine, or combined therapy)\n4. Signed informed consent form\n\nExclusion Criteria:\n\n1. Severe chikungunya fever;\n2. Participation in another drug clinical trial within the past 3 months;\n3. Any other condition deemed by the investigator as unsuitable for enrollment.",{"count":186,"type":20},600,"This study aims to evaluate the effectiveness and safety of Chinese Medicine-used alone or combined with Western medicine-in treating chikungunya fever, a mosquito-borne viral disease causing fever, rash, and severe joint pain. With recent outbreaks in China (including over 3,000 cases in Foshan, Guangdong) and no specific antiviral treatment available, Chinese medicine may offer a valuable therapeutic option based on its symptom-relief and syndrome-specific approach.",[189],"Chikungunya Fever","2025-08-06",{"date":172,"type":33},{"date":193,"type":33},"2025-07-26",{"date":195,"type":20},"2026-12-26",{"name":39,"class":40},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":206,"conditions":207,"keywords":210,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":4},"100600971","an-epidemiological-and-long-term-endpoint-registry-study-on-disease-syndrome-correlation-patterns-in-comorbid-population-with-diabetes-and-ischemic-cardio-cerebrovascular-disease-100600971","NCT07104422","An Epidemiological and Long-Term Endpoint Registry Study on Disease-Syndrome Correlation Patterns in Comorbid Population With Diabetes and Ischemic Cardio-Cerebrovascular Disease","Diabetes","Inclusion Criteria:\n\n* Aged ≥ 18 years Diagnosed with comorbidities relevant to \"toxin-damaged collaterals\" theory (e.g., type 2 diabetes mellitus with cardiovascular\u002Fcerebrovascular disease).\n\nVoluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n* Acute infectious diseases, malignant tumors, or autoimmune disorders. Mental illness or cognitive impairment affecting symptom assessment.",{"count":205,"type":20},12000,"Explore the characteristics of TCM syndrome elements and distribution patterns of syndrome types in comorbid populations; Screen for \"high-risk syndrome patterns\" and frequently co-occurring complex syndromes; Identify characteristic syndrome patterns at key stages: acute phase, recovery phase, and upon occurrence of endpoint events; Investigate the temporal evolution of TCM syndrome patterns and the disease-syndrome correlation patterns in comorbid patients.",[208,209],"Type 2 Diabetes Mellitus (T2DM)","Cardiovascular Complications",[211,212,213,214],"Diabetes comorbidities","Cardiovascular-cerebrovascular diseases","Real-world registry study","Disease-syndrome correlation","2025-07-29",{"date":217,"type":33},"2025-08-05",{"date":219,"type":20},"2025-08-15",{"date":221,"type":20},"2028-07-30",{"name":39,"class":40},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":71,"enrollmentInfo":230,"targetDuration":4,"studyType":21,"phases":232,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":41},"100600550","acupuncture-combined-with-chemotherapy-for-gastric-cancer-after-surgery-100600550","NCT07098949","Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery","Multicenter Randomized Controlled Clinical Study on Acupuncture Combined With Adjuvant Chemotherapy for the Prevention of Recurrence and Metastasis After Gastric Cancer Surgery","Inclusion Criteria:\n\n1. Patients with gastric cancer who have undergone R0 resection of the stomach\u002F distal stomach with D2 lymphadenectomy and are planned to receive postoperative adjuvant chemotherapy\n2. Postoperative pathological diagnosis of gastric cancer, with pathological staging of pII\u002FpIII (American Joint Committee on Cancer, AJCC)\n3. No recurrence or metastasis confirmed by imaging examination\n4. Performance Status (PS) score of 0-2\n5. Age between 18 and 75 years\n6. Normal bone marrow, liver, and kidney function:\n\n   * Normal bone marrow function: Neutrophil count ≥1.5×10\\^9\u002FL, platelet count ≥100×10\\^9\u002FL, hemoglobin ≥90g\u002FL\n   * Normal kidney function: Serum creatinine ≤1.5mg\u002Fdl (133μmol\u002FL) and\u002For creatinine clearance ≥60ml\u002Fmin\n   * Normal liver function: Total serum bilirubin level ≤1.5 times the upper limit of normal (ULN), serum aspartate aminotransferase (AST) \\& alanine aminotransferase (ALT) ≤2.5 times ULN\n7. Signed informed consent, and the patient voluntarily accepts treatment according to this protocol\n\nExclusion Criteria:\n\n1. Unable to complete baseline assessment\n2. Individuals with a fear of acupuncture\n3. Those planning to receive postoperative adjuvant radiotherapy\n4. History of blood system diseases, organ transplant history, or those requiring long-term oral immunosuppressants\n5. Individuals with implanted cardiac pacemakers\n6. Those who have received acupuncture treatment within the past 6 weeks\n7. Fever within 3 days prior to enrollment with a temperature above 38°C or clinically significant infections(Subject to enrollment once infection is managed)\n8. Currently receiving or having used the investigational drug or device within 4 weeks prior to the first intervention of the study\n9. Presence of other primary tumors\n10. Pregnant or breastfeeding women, individuals with mental illness, intellectual or language disabilities, those lacking legal capacity, or those whose medical or ethical reasons affect the continuation of the study",{"count":231,"type":20},346,[23],"This multicenter, randomized, parallel-group clinical trial aims to evaluate the efficacy of acupuncture combined with adjuvant chemotherapy in patients with gastric cancer who have undergone surgery. Participants will be randomly assigned in a 1:1 ratio to receive either acupuncture or sham acupuncture during the adjuvant chemotherapy period.",[235],"Gastric Cancer",[235,27,237,238],"Adjuvant chemotherapy","Recurrence","2025-07-25",{"date":241,"type":33},"2025-08-01",{"date":243,"type":20},"2025-08",{"date":245,"type":20},"2029-02",{"name":39,"class":40},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":21,"phases":257,"briefSummary":258,"conditions":259,"keywords":262,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":272,"locationsCount":94},"100599748","phase-4-traditional-chinese-medicine-intervention-for-ischemic-cardiovascular-disease-comorbid-with-diabetes-mellitus-an-efficacy-comparative-study-100599748","NCT07088523","Traditional Chinese Medicine Intervention for Ischemic Cardiovascular Disease Comorbid With Diabetes Mellitus: An Efficacy Comparative Study","TICDEs","Inclusion Criteria:\n\n* Age\\>18 years;\n* Met the diagnostic criteria for myocardial infarction and type 2 diabetes mellitus;\n* Within 72 hours of myocardial infarction onset;\n* Met the diagnostic criteria of \"toxins damaging collaterals\"；\n* Voluntary participation in the study with consent forms signed.\n\nExclusion Criteria:\n\n* Long-term (\\>20 min) cardio-pulmonary resuscitation (CPR);\n* Critical illness due to STEMI (such as serious cardiogenic shock, uncontrolled acute left heart failure or pulmonary edema, malignant arrhythmias, explicit mechanical complications, etc. );\n* Suspected aortic dissection or acute pulmonary embolism;\n* Bleeding history in any organ system within 1 month, or presence of active hemorrhage at any part of the body, or known hemorrhagic constitution, or severe coagulation disorder or current usage of anticoagulants;\n* Uncontrolled severe diabetic ketoacidosis;\n* Serious hepatic dysfunction or serious renal dysfunction ( ALT\u002FAST≥3 ULN or eGFR\\\u003C30mL\u002Fmin\u002F1.73 m2 or equiring dialysis );\n* Serious COPD or respiratory failure;\n* Severe infection (such as positive blood cultures, septic shock, and septic pneumonia, etc.);\n* Neuropsychiatric system diseases or unconscious and unable to cooperate with examination and treatment;\n* Malignancies or other conditions with expected survival time\\\u003C1 year or unsuitability to participate in this study due to other diseases;\n* Allergy to the ingredients of the research drugs;\n* Women who are in pregnancy or nursery;\n* Participation in clinical trial of other traditional Chinese medicine.","80 Years",{"count":256,"type":20},4205,[161],"The population with comorbid ischemic cardiovascular disease (ICD) and diabetes mellitus (DM) has been growing rapidly, characterized by high mortality rates and frequent vascular event recurrence. DM exacerbates ischemic heart disease incidence and significantly elevates mortality in this comorbid population. Polypharmacy in these patients increases risks of adverse drug interactions and imposes substantial healthcare burdens. The pathological mechanisms of comorbidity demonstrate significant alignment with the TCM. Experimental studies indicate that Xintong Oral Liquid can ameliorate myocardial ischemia through multiple mechanisms to improve vascular endothelial function and microvascular dysfunction. This study aims to investigate the long-term effects of TCM intervention in patients with comorbid ICD and DM within 72 hours of symptom onset, and to evaluate whether the TCM treatment approach-centered on Xintong Oral Liquid within an integrated general treatment and syndrome differentiation framework-demonstrates superiority over control therapy in reducing 90-day major adverse cardiovascular and cerebrovascular events (MACCEs).",[260,261],"Diabete Mellitus","Ischemic Cardiovascular Disease",[260,263,264,265],"Ischemic cardiovascular disease","real-world","Xintong Oral Liquid","2025-07-20",{"date":268,"type":33},"2025-07-28",{"date":270,"type":20},"2025-07-31",{"date":176,"type":20},{"name":39,"class":40},{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":71,"enrollmentInfo":280,"targetDuration":4,"studyType":21,"phases":282,"briefSummary":283,"conditions":284,"keywords":287,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":94},"100520331","xcht-for-irinotecan-induced-gut-toxicities-randomized-controlled-trial-100520331","NCT06055179","XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)","Mechanistic and Pharmacokinetic Studies of Classical Chinese Formula Xiao Chai Hu Tang (XCHT) Against Irinotecan-Induced Gut Toxicities(Clinical Study Part:Randomized Controlled Trial)","Inclusion criteria:\n\n1. Malignant tumor confirmed by histology or cytology;\n2. Age ≥ 18 years old, ≤ 75 years old;\n3. ECOG score of the patient ≤ 2 points;\n4. Patients who have diarrhea worse than grade 2 due to irinotecan chemotherapy (the last dose of irinotecan is administered within 1 month);\n5. Patients who plan to receive 3 cycles of irinotecan chemotherapy (the dose of irinotecan ≥ 125mg\u002Fm2);\n6. Normal organ functions which can meet the requirements for systemic chemotherapy:\n\n   * Normal bone marrow function: absolute neutrophil count (ANC) ≥ 1.5×109\u002FL, PLT ≥ 100×109\u002FL, hemoglobin ≥ 90g\u002FL;\n   * Normal renal functions: serum creatinine ≤ 1.5mg\u002Fdl (133μmol\u002FL) and\u002For creatinine clearance ≥ 60ml\u002Fmin;\n   * Normal hepatic functions: total serum bilirubin level ≤ 1.5 times of the upper limit of normal value (ULN), serum aspartate aminotransferase (AST) \\& alanine aminotransferase (ALT) ≤ 2.5× ULN; AST \\& ALT ≤ 5 × ULN if abnormal hepatic functions are caused by a potentially malignant tumor.\n7. Patients who can understand and complete the questionnaires in the case report form;\n8. Patients who can understand and sign the informed consent form, is well compliant, and can be followed up.\n\nExclusion Criteria:\n\n1. Patients with diagnosed depression, obsession or\u002Fand schizophrenia;\n2. Patients with diagnosed inflammatory bowel diseases (including Crohn's disease, ulcerative colitis)\n3. Patient with active tuberculosis and other uncontrolled infections;\n4. Patient who has previously received radiotherapy on the abdominal cavity or pelvic cavity;\n5. Pregnant or lactating women;\n6. Patient who previously had or is now having thromboembolic events.",{"count":281,"type":20},98,[23],"Randomized double-blind placebo-controlled trial (RCT) study, to determine the impact of XCHT on irinotecan-induced severe delayed-onset diarrhea (SDOD), and to determine the feasibility of using plasma raloxifene-4'-glucuronide as a probe for intestinal UGT activity.",[285,286],"Xiao Chai Hu Tang","Irinotecan-induced Diarrhea",[288,289,285,290,291],"Malignant tumor","Irinotecan-induced diarrhea","Classical Chinese Formula","pharmacokinetic mechanism","2025-06-29",{"date":294,"type":33},"2025-07-01",{"date":296,"type":33},"2024-03-08",{"date":298,"type":20},"2026-12-01",{"name":39,"class":40},{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":254,"enrollmentInfo":307,"targetDuration":4,"studyType":21,"phases":309,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":4},"100562892","chg0521-oral-coating-in-patients-with-solid-tissue-tumorrecurrentmetastatic-tscc-100562892","NCT06609070","CHG0521 Oral Coating in Patients with Solid Tissue Tumor\u002FRecurrent\u002FMetastatic TSCC","CHG0521 Oral Coating; TSCC","Inclusion Criteria:\n\n* 1\\. Age range: 18-80 years, encompassing both males and females. 2. Confirmation of tongue squamous cell carcinoma through histopathology or cytology is required.\n\n  3\\. Patients who are deemed unsuitable for surgery, have surgical indications but decline the treatment, or experience relapse and metastasis after surgery with no further surgical options available.\n\n  4\\. No concurrent use of other traditional Chinese medicine orally or externally within the past 3 months.\n\n  5\\. Presence of at least one measurable lesion according to RECIST 1.1 criteria. 6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\n  7\\. Expected survival time should be equal to or greater than 3 months. 8. Liver function indicators: total bilirubin level ≤1.5 times the upper limit of normal (ULN), AST and ALT levels ≤2.5 times ULN (or ≤5 times ULN in case of liver metastasis).\n\n  9.Renal function indicators: serum creatinine (CRE) ≤1.5×ULN and calculated creatinine clearance (using Cockcroft-Gault formula) ≥60 ml\u002Fmin.\n\n  10.The functionality of vital organs should be essentially normal.\n\nExclusion Criteria:\n\n* 1\\. Patients with tongue squamous cell carcinoma who have undergone tumor resection without any residual tumor; 2. Patients with a known allergy to any therapeutic ingredient or a history of hypersensitivity or allergic constitution; 3. Patients who have experienced a severe infection within 4 weeks prior to the first use of the investigational drug, and whose common adverse reaction criteria were graded as \\>2; 4. Patients with a history of immune deficiency, organ transplantation, or allogeneic bone marrow transplantation; 5. Patients currently enrolled in another concurrent clinical study; 6. Pregnant and lactating women.",{"count":308,"type":20},30,[23],"This is a prospective single-arm loading test study of CHG0521 oral coating in patients with solid tissue tumor\u002Frecurrent\u002Fmetastatic TSCC",[312,313],"Squamous Cell Carcinoma","Squamous Cell Carcinoma of the Oral Cavity","2024-09-20",{"date":316,"type":33},"2024-09-23",{"date":318,"type":20},"2024-10-15",{"date":320,"type":20},"2026-08-31",{"name":39,"class":40},{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":71,"enrollmentInfo":329,"targetDuration":4,"studyType":21,"phases":331,"briefSummary":333,"conditions":334,"keywords":338,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":94},"100535711","phase-2-study-of-fruquintinib-combined-with-tegafur-gimeracil-oteracil-in-patients-with-metastatic-colorectal-cancer-100535711","NCT06255379","Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer","An Open, Single-arm, Multicenter, Prospective Phase II Study of Fuquinitinib Combined With Tegafur Gimeracil Oteracil in the Third-line Treatment of Patients With Advanced Metastatic CRC","Inclusion Criteria:\n\n1. ≥ 18 and ≤ 75 years of age;\n2. Have fully understood and voluntarily sign the ICF for this study (the icf must be signed before any trial-specific procedures are performed);Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure;\n3. Histologically and\u002For cytologically documented metastatic colorectal adenocarcinoma;\n4. Refractory to at least second line standard treatment containing fluorouracil, oxaliplatin and irinotecan;\n5. At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan or 20mm by conventional CT scan);\n6. ECOG performance status of 0-1;\n7. Life expectancy ≥ 12 weeks;\n8. No previous treatment with vascular endothelial growth factor receptor (VEGFR) inhibitor (TKI);\n9. Adequate hepatic, renal, heart, and hematologic functions;\n10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Any factors that influence the usage of oral administration or any disease or condition that affects drug absorption;\n3. Previous treatment with Tegafur Gimeracil Oteracil ;\n4. Participated in clinical trials of other drugs within four weeks before enrollment;\n5. Received other systemic anti-tumor therapy within 4 weeks before enrollment, including chemotherapy, signal transduction inhibitors, hormone therapy and immunotherapy;\n6. International normalized ratio (INR) \\> 1.5 or partially activated prothrombin time (APTT) \\> 1.5 × ULN;\n7. Clinically significant electrolyte abnormalities;\n8. Subjected with hypertension that cannot be controlled by drugs, which is specified as: systolic blood pressure ≥ 140 mmHg and \u002F or diastolic blood pressure ≥ 90 mmHg;\n9. Unrelieved toxic reactions higher than CTCAE V5.0 grade 1 caused by any previous anti-cancer treatment;\n10. Incomplete healing of skin wound, surgical site, traumatic site, severe mucosal ulcer or fracture;\n11. Conditions that may cause gastrointestinal bleeding and perforation determined by the researcher;\n12. History of arterial thrombosis or deep venous thrombosis within 6 months before enrollment;\n13. Stroke and \u002F or transient cerebral ischemia occurred within 12 months before enrollment;\n14. Cardiovascular diseases with significant clinical significance;\n15. LVEF\\\u003C50%;\n16. Congestive heart failure New York Heart Association (NYHA) grade \\> 2;\n17. Evidence of CNS metastasis;\n18. Previous treatment with VEGFR inhibition;\n19. Ventricular arrhythmias requiring drug treatment;\n20. Proteinuria ≥ 2+ (1.0g\u002F24hr);\n21. Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy;\n22. Other malignant tumors in the past 5 years, except skin basal cell or squamous cell carcinoma after radical surgery, or cervical carcinoma in situ;\n23. Active infection that is not controlled clinically, such as acute pneumonia, active hepatitis B or hepatitis C;\n24. By judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the patient or affect the completion of the study.",{"count":330,"type":20},52,[332],"PHASE2","This is an Open, Single-arm, Multicenter, Prospective Phase II Study of Fuquinitinib Combined With Tegafur Gimeracil Oteracil in the Third-line Treatment of Patients With Advanced Metastatic CRC",[335,336,337],"Metastasis Colorectal Cancer","Colon Cancer","Rectal Cancer",[339,340,341,342],"Colorectal cancer","Fruquintinib","Tegafur Gimeracil Oteracil","mCRC","2024-04-26",{"date":345,"type":33},"2024-04-29",{"date":347,"type":20},"2024-05-06",{"date":349,"type":20},"2027-03-21",{"name":39,"class":40},{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":102,"sex":16,"minAge":359,"maxAge":360,"enrollmentInfo":361,"targetDuration":363,"studyType":134,"phases":4,"briefSummary":364,"conditions":365,"keywords":372,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":94},"100463530","the-dampness-syndrome-of-chinese-medicine-cohort-study-100463530","NCT05315895","The Dampness Syndrome of Chinese Medicine Cohort Study","A Multi-Center Prospective Cohort Study of Dampness Syndrome in China","DACOS","Inclusion Criteria:\n\n1. Residents aged 30 to 79, whose residence is consistent with their registered permanent residence location;\n2. Residents who voluntarily participate in the project, agree to the collection of their biological information, and sign the informed consent form;\n3. Residents who have no mental illness and other related diseases, and display a normal ability of expression and understanding;\n\nExclusion Criteria:\n\n1. Residents who reject collaboration;\n2. Residents who allow no follow-up visits.","35 Years","79 Years",{"count":362,"type":20},100000,"5 Years","The researchers plain to build a large-scale, longitudinal, prospective cohort characterized by TCM dampness syndrome. With the biobank of this cohort the investigators want to find the causality between TCM dampness syndrome and clinical chronic diseases and a new way to treat clinical disease.",[366,367,368,369,370,371],"Chronic Disease","Cancer","Dementia Alzheimers","Metabolic Disease","Aging","Alzheimer Disease, Early Onset",[373,374,375],"Dampness Syndrome","multi-center study","prospective cohort study","2022-11-14",{"date":378,"type":33},"2022-11-15",{"date":380,"type":33},"2022-06-06",{"date":382,"type":20},"2028-03-30",{"name":39,"class":40},{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":102,"sex":16,"minAge":391,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":394,"conditions":395,"keywords":397,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":401,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":94},"100424263","proteomics-study-of-mild-cognitive-impairment-and-alzheimers-disease-100424263","NCT04804618","Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease","Exploring Research on Early Warning Indicators of Protein in Patients With Mild Cognitive Impairment and Alzheimer's Disease","Inclusion Criteria:\n\n1. Older than 55-year-old，male or female.\n2. patients meet the diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease(AD) or whose family members were diagnoed with AD\n3. Complete self-rating scale for memory impairment (AD-8 scale)\n4. Those who agree to participate in clinical research and sign informed consent.\n\nExclusion Criteria:\n\n1. Patients with acute cardiovascular and cerebrovascular diseases, acute infections (pneumonia, urinary tract infection, oral infection, digestive tract infection), severe renal dysfunction, and uremia;\n2. Pregnant or lactating women;","55 Years",{"count":393,"type":20},650,"This study intends to adopt standardized and rigorous cross-sectional research, collect biological specimens (including blood, feces, urine, saliva and tongue coating) from eligible subjects, and use liquid chromatography\u002Fmass spectrometry (LC-MS\u002FMS) technology to explore early warning indicators of protein in patients with mild cognitive impairment and Alzheimer's disease",[371,396],"Protein; Disease",[398,399,400],"Alzheimer Disease","biomarker","protein",{"date":378,"type":33},{"date":403,"type":33},"2021-06-01",{"date":405,"type":20},"2026-06-30",{"name":39,"class":40},""]